Harvard Psilocybin Project

The Harvard Psilocybin Project was a psychological research program founded at Harvard University in 1960 by Timothy Leary and Richard Alpert, later known as Ram Dass. It brought psilocybin into experiments with hundreds of volunteers, but its controversial departure from Harvard also became a turning point in the public story of psychedelic research. Its fame has often made it seem like the beginning of serious academic work on psychedelics; the historical record presented here places it instead near the end of an already fertile period of research, and at the center of a story that continued well beyond Cambridge.

Origins and Research Program

Leary established the project in the fall of 1960, soon after a life-changing psilocybin experience in Mexico. Based in Harvard’s Department of Social Relations, the team included graduate student Ralph Metzner. The researchers administered psilocybin to hundreds of volunteers in what the project described as a naturalistic setting, and later began working with LSD as well.

The project’s activities extended into settings beyond its volunteer studies. Researchers conducted experiments with prisoners at Concord State Prison and with theology students at Boston University’s Marsh Chapel. These different contexts placed psychedelic research in contact with questions of behavior, religious experience, and psychological change, while also increasing the public and institutional scrutiny surrounding the work.

Controversy and Closure

The project was engulfed in controversy in 1962. One consequential allegation was that Alpert had given psilocybin to an undergraduate, in violation of the project’s agreement with Harvard. The university controversy ended the project’s standing at Harvard; the account identifies Leary’s dismissal from the university in 1963 as a landmark in the episode. Leary and Alpert then established a successor organization in Cambridge, outside Harvard, the International Federation for Internal Freedom.

The Harvard dispute unfolded amid a broader change in the climate surrounding psychedelic research. By 1962 and 1963, quantities of bootleg LSD had appeared on the street, and people experiencing acute reactions were arriving in emergency rooms and psychiatric wards. Mainstream psychiatry increasingly treated LSD as a cause of mental illness rather than a possible treatment. Public accounts amplified danger, including a widely publicized claim that LSD could damage chromosomes, later discredited with far less attention. These developments do not reduce the Harvard controversy to a single cause, but they show how the project’s institutional conflict coincided with a widening loss of confidence in psychedelic research.

A Project in a Larger Research History

The project’s visibility can distort the chronology of the field. Leary’s public prominence encouraged the impression that serious academic psychedelic research began with Harvard and ended with his departure. In the broader history described here, research had already developed during the previous decade in Saskatchewan, Vancouver, California, and England. A comparatively small and often overlooked group of scientists, therapists, and amateurs had built therapeutic approaches and practical protocols before Leary began his work at Harvard.

Nor did psychedelic research end when the Harvard project did. The broader American research landscape collapsed by the end of 1966: Sandoz withdrew LSD-25 from circulation in April, and in October the FDA ordered researchers across the country to stop their work. The Maryland Psychiatric Research Center at Spring Grove was an exception and continued its research for years. Harvard’s closure thus belongs to a wider unraveling, not a clean division between a brief Harvard beginning and a total end.

Legacy and Influence

The project remains important both for the research it undertook and for the disproportionate place it occupies in popular memory. The account argues that Leary’s success in shaping the public narrative obscured earlier work and the less celebrated people who had developed ways to use psychedelics therapeutically. Reconsidering Harvard therefore changes the emphasis: rather than treating it as the origin of the field, it becomes one highly visible episode within a broader history of research, institutional conflict, and knowledge that was later difficult to recover.

That history also had an underground afterlife. Later guides interviewed in the Bay Area and elsewhere often traced their professional lineages to the 1950s and 1960s generation, including Leary, frequently through one of his graduate students, as well as Stanislav Grof, Al Hubbard, or Leo Zeff. Researchers in the revival beginning in the late 1990s excavated the earlier period’s intellectual and clinical record. The Harvard project was therefore neither the whole beginning nor the final word: its fame helped define the public image of psychedelic research, while the practices and research networks surrounding it proved more extensive and enduring than that image suggested.